Incyte shifts to multi-franchise biotech with 17% sales growth and key 2026 clinical readouts ahead

Incyte Corporation is evolving from relying mainly on its Jakafi drug to becoming a diversified biotech company with multiple late-stage pipeline assets. Its 2Q26 results showed a 17% increase in underlying net sales, broad portfolio growth, and strong operating leverage despite some one-time benefits. The company’s upcoming clinical trial results in the second half of 2026 across dermatology, hematology, and oncology will be crucial to validate its growth strategy. While near-term earnings may be compressed due to reinvestment, Incyte’s strong cash reserves and potential for significant growth post-2026 support its valuation.